AbbVie Inc. Operating CF per Share

Operating CF per Share of ABBV for past 10 years: annual, quarterly and twelve month trailing (TTM) including Operating CF per Share growth rates and interactive chart. Total operating cash flow in a period divided by the weighted average number of shares outstanding. A company with $100 million in operating cash flow and 10 million weighted average shares will have operating cash flow per share of $10.


Highlights and Quick Summary

  • Operating CF per Share for the quarter ending June 29, 2020 was 1.88 (a -27.19% decrease compared to previous quarter)
  • Year-over-year quarterly Operating CF per Share decreased by -39.02%
  • Annual Operating CF per Share for 2019 was 9.0 (a 3.25% increase from previous year)
  • Annual Operating CF per Share for 2018 was 8.71 (a 39.62% increase from previous year)
  • Annual Operating CF per Share for 2017 was 6.24 (a 43.76% increase from previous year)
  • Twelve month Operating CF per Share ending June 29, 2020 was 8.95 (a -6.18% decrease compared to previous quarter)
  • Twelve month trailing Operating CF per Share decreased by -1.43% year-over-year
Trailing Operating CF per Share for the last four month:
29 Jun '20 30 Mar '20 30 Dec '19 29 Sep '19
8.95 9.54 9.0 9.08
Visit stockrow.com/ABBV for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Operating CF per Share of AbbVie Inc.

Most recent Operating CF per Shareof ABBV including historical data for past 10 years.

Interactive Chart of Operating CF per Share of AbbVie Inc.

AbbVie Inc. Operating CF per Share for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2020 1.88 2.58
2019 2.21 3.08 1.67 2.04 9.0
2018 2.2 2.99 1.83 1.66 8.71
2017 1.62 2.05 1.26 1.32 6.24
2016 0.95 0.89 1.18 1.32 4.34
2015 1.21 1.3 1.13 0.99 4.64
2014 -0.36 1.12 1.08 0.39 2.23
2013 0.78 1.13 1.28 0.75 3.94
2012 0.6 1.43 0.99 1.01 4.02
2011 0.66 1.36 1.37 0.0 3.96
2010 0.0 3.16
2009 0.0 0.0

Business Profile of AbbVie Inc.

Sector: Medical
Industry: Drugs
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the United States, Japan, Germany, Canada, France, Spain, Italy, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides SYNAGIS that protects at-risk infants from severe respiratory disease; KALETRA, a prescription anti-HIV-1 medicine; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; and Lupron, a product for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; and Sevoflurane, an anesthesia product. It has collaborations with Calico Life Sciences LLC; Alector, Inc.; Janssen Biotech, Inc.; Jacobio Pharmaceuticals; and Genmab A/S. The company was incorporated in 2012 and is based in North Chicago, Illinois.